News
Articles
Oncopanel expanded with new genes and the use of digitalMLPA
Genes tested by NGS: APC, ATM, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, EPCAM, ERCC2, ERCC3, FANCC, FANCM, FH, FLCN, GREM1, MET, MLH1, MLH3, MSH2, MSH6, MUTYH, NBN, NF2, PALB2, POLD1, POLE, PRKAR1A, PTEN, PTCH1, RAD50, RAD51C, RAD51D, RET, SDHB, SLX4, SMAD4, SMARCB1, STK11, SUFU, TP53, VHL, WRN, WT1, UNC13D, MEN1, MITF, NTHL1, NF1, CHEK2, PMS2, RB1, PDK1, PDK2, PKHD1, PRSS1, PRSS2, SCG5, SPINK1, CTRC and HOXB13. Of which now newly introduced genes for NGS: MITF, PDK1, PDK2, PKHD1, PRSS1, PRSS2, SCG5, SPINK1, CTRC and HOXB13.
Enhanced testing of the DPYD gene
Following the recommendation of the European Medicines Agency CPIC (Clinical Pharmacogenetics Implementation Consortium), GHC Genetics laboratory has expanded testing of the DPYD gene (5-fluorouracil dosage) to test additional variants:
We have established cooperation with the Veronica patient organisation.
We are pleased to announce that in February we established cooperation with the Veronica patient organization. The Veronica patient organisation brings together patients with endometrial, vulvar, ovarian and cervical cancer and women with the BRCA 1 and BRCA 2 genetic mutations.
Join the Czech genome analysis project!
Have you ever wondered who your ancient ancestors were? Would you like to know more about your origins? Then we have a unique opportunity for you!